• Unaudited revenue of $15.3m, up 12% QoQ and 53% YoY
• Sample volumes grew 18% QoQ and 53% YoY
• Signed two new contracts, bringing total to 56 contracted units

Chrysos Corporation Ltd (ASX:C79) reported strong Q2 FY25 results, with unaudited revenue of $15.3m, reflecting a 12% increase Quarter-on-Quarter (QoQ) and a 53% increase Year-on-Year (YoY). This growth was driven primarily by international revenue and sample volume growth. Sample volumes totalled 1.6m, reflecting 18% growth QoQ and 53% growth YoY. The company signed two new contracts with OceanaGold Corporation and SGS, building on four contracts in Q1 FY25 and bringing the total number of contracted units to 56. Three units were deployed during the quarter, including a second unit at the Barrick-Newmont NGM complex in Nevada, a unit in Orange, New South Wales for SGS, and Chrysos' first Alaskan-based unit, bringing the total number of deployed units to 34. The company remains well-funded to support continued PhotonAssay unit growth, with a cash position of $26.6m and $95m in undrawn debt available.

Chrysos is on track to achieve its FY25 Guidance of $60-$70m in revenue and $9-$19m in EBITDA.

Chrysos continues to monitor market indicators for signs of a broader improvement in the gold industry cycle and is ready to capture this upside through latent unit capacity.